WAVE Life Sciences Enters Collaboration with Pfizer
News May 12, 2016
WAVE Life Sciences Ltd. has announced that it has entered into a research, license and option agreement with Pfizer Inc. for the potential development of nucleic acid therapies aimed at silencing the underlying causes of debilitating metabolic diseases. The collaboration will focus on genetically defined targets and bring together WAVE’s proprietary stereo pure drug development platform, across antisense and RNAi modalities, along with GalNAc and Pfizer’s hepatic targeting technology for enhanced delivery to the liver.
Under the terms of the agreement, WAVE will advance up to five programs from discovery through to the selection of clinical candidates, at which point Pfizer may elect to exclusively license the programs and undertake further development and potential commercialization. Two targets have been declared upon initiation of the agreement, including WAVE’s Apolipoprotein C-III program, with the remaining targets to be declared within eighteen months.
In addition, WAVE has received rights to Pfizer's hepatic targeting technology, which WAVE may elect to use for hepatic programs beyond the collaboration. Should WAVE use this technology, Pfizer is eligible to receive potential development and commercial milestone payments from WAVE. Pfizer is also eligible to receive tiered royalties on sales of any products that include Pfizer’s hepatic targeting technology.
WAVE’s platform enables the design and development of stereo pure nucleic acid therapeutics, which are optimized across multiple dimensions of pharmacology, including efficacy, stability, specificity and safety. WAVE’s platform offers the flexibility to design therapeutics across multiple modalities, including antisense, RNAi and exon-skipping.
Per the agreement, Pfizer agreed to pay $40 million upfront, $30 million of which is in the form of an equity investment in WAVE at a price of $16 per share. In addition, assuming five potential products are successfully developed and commercialized, WAVE may earn up to $871 million in potential research, development and commercial milestone payments from Pfizer, plus royalties, tiered up to low double-digits, on sales of any products that may result from the collaboration.
“We are excited about this collaboration with Pfizer, which will enable us to combine WAVE’s innovative platform capabilities with Pfizer’s metabolic development and commercialization capabilities with the goal of making meaningful medicines for patients,” said Paul Bolno, M.D., MBA, President and Chief Executive Officer of WAVE Life Sciences.
“This alliance is consistent with WAVE’s strategy to build and advance a portfolio of medicines for neurological and neuromuscular diseases, while working with partners with deep expertise in other important therapeutic areas. We expect that our existing cash together with the upfront payment will enable us to fund our operating expenses and capital expenditure requirements into 2019.”
“Our collaboration with WAVE represents Pfizer’s commitment to embracing the most modern technologies as therapeutic modalities in our core areas of focus, which we feel will make a significant difference for patients in need,” said Morris Birnbaum, M.D., Ph.D., Senior Vice President and Chief Scientific Officer, Cardiovascular & Metabolic Research Unit, Pfizer.
“To accomplish this, we must commit to the most promising technologies, and we believe that WAVE’s oligonucleotide strategy is among the best. By working together to develop unique, proprietary technologies emerging from both companies, we will explore new liver-targeted approaches to address the cause of genetically defined diseases and interrupt the progression of complex, metabolic disorders.”
"Genetic Jenga" Helps Understand How Our Genes Control Our CellsNews
To fully understand how our cells work, we can't focus on just one gene, but must instead look at combinations of genes. Researchers have published a study which knocked out multiple genes, like removing bricks from a Jenga tower, to better understand how they work together.READ MORE
Southeast Asian Nomads Have Evolved to Hunt Fish UnderwaterNews
The human spleen can release oxygenated blood cells to allow more time underwater without breathing. A new study has identified that the "Sea Nomad" Bajau people of Indonesia have evolved larger spleens that would allow them to remain underwater for longer.READ MORE
Gene Therapy Could End Transfusions for Blood Disorder PatientsNews
Beta-thalassemia patients need a regular dose of red blood cells transfused into their body. A new gene therapy that edits faulty genes in the patients' cells could end this monthly ritual.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018
International Conference on Epigenetics and Epitranscriptomics
Sep 17 - Sep 18, 2018